Published in Cell Cycle on January 01, 2014
microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expression. Chin J Cancer Res (2015) 0.79
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol (1995) 2.57
WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res (2011) 1.59
DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. Proc Natl Acad Sci U S A (2005) 1.57
Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle (2012) 1.44
Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol (1995) 1.38
Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints. Cell Cycle (2014) 0.90
An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol (2009) 3.15
Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literature. Cancer Biol Ther (2006) 2.70
Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle (2011) 2.67
Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther (2010) 1.99
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther (2008) 1.74
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res (2005) 1.74
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol (2012) 1.55
Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot. Cancer Biol Ther (2004) 1.48
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res (2009) 1.41
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res (2010) 1.35
Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol (2004) 1.32
Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res (2011) 1.21
High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res (2007) 1.19
Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther (2008) 1.18
Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer (2011) 1.18
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol (2013) 1.18
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg (2008) 1.17
A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One (2012) 1.15
Small bowel adenocarcinoma. Curr Treat Options Oncol (2009) 1.13
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 1.11
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg (2010) 1.10
Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biol Ther (2008) 1.10
Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle (2011) 1.07
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res (2014) 1.05
Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle (2008) 1.04
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol (2010) 1.03
A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res (2008) 1.02
The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Biol Chem (2002) 0.99
Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology (2006) 0.97
Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. Hepatology (2011) 0.95
HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. Cancer Biol Ther (2012) 0.95
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J Biol Chem (2012) 0.93
Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res (2011) 0.93
Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res (2013) 0.92
Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Mol Cancer Res (2013) 0.92
Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opin Drug Deliv (2010) 0.91
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. PLoS One (2010) 0.90
Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Res (2013) 0.89
Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol Ther (2010) 0.89
HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biol (2013) 0.89
Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer (2012) 0.86
Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer. Cancer Biol Ther (2007) 0.85
Naturally occurring K vitamins inhibit pancreatic cancer cell survival through a caspase-dependent pathway. J Gastroenterol Hepatol (2009) 0.84
High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells. Cancer Res (2007) 0.84
Liver stem cells and molecular signaling pathways in hepatocellular carcinoma. Gastrointest Cancer Res (2007) 0.83
Single nucleotide polymorphism in RECQL and survival in resectable pancreatic adenocarcinoma. HPB (Oxford) (2009) 0.83
Postresection chemotherapy for pancreatic cancer. Cancer J (2012) 0.83
Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. Am J Clin Oncol (2014) 0.83
Future of targeted agents in metastatic colorectal cancer. Colorectal Cancer (2012) 0.81
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer (2015) 0.81
Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: native ribonucleoprotein immunoprecipitation (RIP) assays. Methods Mol Biol (2015) 0.79
The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway. Cancer Prev Res (Phila) (2012) 0.79
Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box". Cancer J (2012) 0.79
Identification of a functional mutation in pp32r1 (ANP32C). Hum Mutat (2004) 0.79
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol (2012) 0.79
Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient. J Surg Res (2011) 0.78
Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma. Oncology (Williston Park) (2015) 0.78
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Invest New Drugs (2012) 0.78
CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapy. Cancer Biol Ther (2010) 0.78
The 'RNA-binding ome': future implications for chemotherapeutic efficacy. Future Oncol (2009) 0.78
Subject review: pancreatic ductal adenocarcinoma in the setting of mutations in the cystic fibrosis transmembrane conductance regulator gene: case report and review of the literature. J Gastrointest Surg (2011) 0.77
Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine. Pharmacogenet Genomics (2014) 0.77
Retrievable inferior vena cava filters in patients with cancer are safe but are they beneficial? Med Oncol (2015) 0.76
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Ann Surg (2016) 0.75
No K01 offered from the NCI What's the message? Cancer Biol Ther (2007) 0.75
A phase I study of oral ixabepilone in patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.75
Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer. Oncology (Williston Park) (2017) 0.75